Thank you, Tova. And also a warm welcome on my behalf. If you look at the third quarter, we had a solid business performance and we continued to strengthen our profitable growth. I will return later in this presentation to discuss how we achieved this, but specifically, the commercial execution, the operational improvements, and infrastructure development continued to strengthen our performance. Net sales grew by 5%, supported by continued high volumes, especially in specialty flows, sales growth in wholesale, and strong sales in special-licensed medicines. Last quarter, we talked a lot about higher fuel prices and also how we could pass costs through to our customers. This is something that we have succeeded with in the third quarter, and I'm really pleased to see that. But during the quarter, we also had a one-off inventory provision, and you will hear more about this in this presentation going forward. That was €0.7 million, and that has affected the group's profitability. So we landed on last year's level during the quarter. We also have stable supply chain operations. We have high volumes in our warehouses, to some extent depending on the geopolitical situation around us. That means we have high inventory levels and also capacity pressures. During the quarter, we also announced that we have revisited our implementation strategy for the ERP and warehouse management programme. That has been revised based on the insights from the first deployment that we did in Sweden at the end of last year. And now the timeline allows us parallel core builds and also direct deployment into Järvenpää. We will also come back to that a little bit later in this presentation. One highlight for this quarter is, of course, Kronans Apotek. We could see another quarter of growth and profitability improvements from Kronans Apotek. It has mainly been by disciplined focus on commercial performance and cost efficiency. And this is also based on the CMD discussions that we had earlier this year. And I know that Max will come back to the figures later on for Kronans Apotek. Moving to the operating environment at Oriola, we saw stable market shares in Finland and Sweden during the quarter. The pharmaceutical distribution market grew in Sweden by around 7%. Sweden showed growth of around 7%. Around 8%. While the growth in Finland remained low with only 0.5%. The geopolitical developments that I mentioned before, especially when it comes to fuel prices and inflationary pressures, are still present, and they contribute to an uncertain operating environment. Looking forward, we can see that pharmaceutical companies are building their inventories to some extent to ensure the availability of pharmaceuticals in our markets. In advisory services, the geopolitical development is continuing. Continuing also to have more cautious customer decision making, like we also mentioned earlier this year. This means longer lead times for new engagements. Consumer confidence in Finland and Sweden has been a little bit different in the two countries. Now during the third quarter in Finland, we can see that it is below the long-term average. While in Sweden in the end of the quarter, it has been rising sharply and is now in line with the historical average.
Then if we go into the services segment, I will start. I will start with the service segment, which consists of the distribution of pharmaceuticals, the value-adding services, and parallel import in the Nordics. The segment we have here also includes Advisory Services and Commercial Data Solutions. Service segments had a net sales growth of 3.7% and landed on €36.4 million, and it has been supported especially by the volumes in the specialty flows, which include the export business, vaccines, and also animal health. We can also see solid development in direct pharmacy deliveries. The adjusted EBITDA improved and landed at €10.1 million, and the improved adjusted EBITDA was driven very much by this net sales growth. As I mentioned before, if you now look back to what we talked about in the CMD, we talked a lot in this segment about strengthening the customer and the joint account planning. And this is something that we can see. We have worked on this a lot during the quarter and also during the full year, and this is now also visible when we look at extended key partnerships and a healthy pipeline across the markets. We have now new key partnerships that will affect both the fourth quarter and the business from 2027. In advisory services, we can see that the sales have remained weak during the quarter. Basically, on the longer lead times in the decision-making from the pharmaceutical company, what we have worked on in our advisory business is to further strengthen our customer engagement and work more on integrated businesses. That is also done in all the different countries where we have advisory services; in Sweden, we launched an AI-enabled commercial data service, and that is something that has also been bought by pharmaceutical companies. This covers the medical information that we have. It takes the data we have in medical information and turns it into actionable product insights that are helping the pharmaceutical companies now in their decision-making. Then, if we continue with the product segment, the segment consists of the wholesale of traded goods and over-the-counter products, as well as our own brands and special-licensed medicines that we have in Finland and Sweden. And the segment also includes the dose dispensing business that we have in Finland. The net sales in this segment grew by 8.8% and landed at €16.8 million, driven especially by wholesale growth overall and strong sales of special-licensed medicines. That has been a part of this growth, as well as the dose dispensing business in Finland. I am also pleased to see that we have now started to sell to one new customer in Sweden. And that is a new specialty retail customer that we have brought into our customer pipeline. The adjusted EBITDA was slightly lower than last year. It landed at €1.7 million. The reason for this is this one-off product inventory provision of €0.7 million that I mentioned earlier. That is then affecting this segment negatively.
If you then look here at what we discussed at the CMD, we also talked about how we work with the customer, as well as how we work with the product portfolio. In this segment, we have now continued to align the product portfolio and also take the products to the growing sales channels. And that is something that we can see in the results, especially in the sales. We will continue now to develop our own brands, as we have also done during the quarter. And that includes both how we price the products, how we do the offering to the customers, and also how we strengthen the competitiveness in these product groups compared to our other competitors. We continue to see that the recent launches have been well received and have gained new listings with our customers.
Normally, we talk quite a lot about the big investments that we do at Oriola. I would now like to take the opportunity to talk about the continuous improvements that we, in fact, make every day in our business. And we will today focus a little bit here on what we do in the supply chain and the efficiency that we drive here. Supply chain is one of the biggest costs, of course, that we have in Oriola. It is crucial that we work on continuous improvements every day. As I mentioned before, we also have higher volumes in our warehouses. And that is, of course, increasing the capacity pressure that we have in our warehouses. What we do then to balance these volumes is, of course, to use external warehousing. And this is something that we work with to maximize the net income and the profitability that we have, and also how to handle new customers and growing stock levels. On top of this, we work a lot with transportation, which is one of the major cost elements that we have in Oriola. And it is, of course, crucial to work with route planning and delivery accuracy, as well as streamline the tools in the sorting processes and focus on route optimization. Here we would like to mention the route optimization in northern Sweden. If you look at the map, you can see that northern Sweden does not have many inhabitants, but there are a lot of roads and many kilometers between different cities. So this is also a way of taking down the cost of transportation. AI and digital tools are something that we have mentioned frequently when it comes to our advisory business. But this is also something that we use in distribution or our operations. So here in our supply chain, we are working with digital tools and AI, for example, to use in inventory planning. This means that we can have the right product in the right volumes at the right sites to be able to maintain high picking accuracy for our customers. And also that we release the working capital in our balance sheet. But with this, we will then turn to what we normally discuss. And those are the strategic projects that we are working on. And what we talked about in the CMD is that we should double the adjusted EBITDA by 2029 and strengthen the foundation for our future growth, and that this strategic project is a vital part of reaching that goal. During the quarter, we have revised and updated the timeline for the ERP and warehouse management programme. I can assure you that this has not changed and that we still have the goal to double the adjusted EBITDA by 2029. It is still there. What we have revised now in the ERP and warehouse management programme is that we have taken the learnings from the first deployment and implemented a new strategy and programme based on that, while also ensuring the Järvenpää distribution centre is included at the end of this period, and we have strengthened the programme and the programme governance.
We are taking more ownership into our own business. So the internal organization has been strengthened, taking more ownership of the total programme. We have also appointed a new implementation partner in this process. The revised timeline has been extended to 2028 to be balanced with the Järvenpää distribution centre, and we will take a direct deployment into the distribution centre. The investment has now been revised and landed on €54 million, whereas it was previously €35 million. But this enables us now a parallel core build in Sweden and in Finland. This is followed by the phased implementation of our ERP and warehouse management programme as mentioned earlier. Of course, we are also doing some, in this scope, smaller projects with the warehouse automation upgrade. This is something that is very crucial for Sweden, where we can see that we will have the possibility in the first quarter next year to get more volumes through Enköping automation, and that will support the growth in the business in both distribution and wholesale. And I will also mention here that the Järvenpää distribution centre is continuing to advance according to the schedule. And with this, I conclude.
That concludes the business highlights, and I will now leave the floor to Måns.